Abstract: Due to genetic and personal variances, patients are treated by different therapeutic approaches to obtain the best outcome. To reach precision medicine for clinical unmet need, we must have a clearer picture in basic knowledge of diseases. Our center will utilize multiple omic approaches to understand in depth the mechanisms of three clinical unmet need diseases: infectious diseases, stress medicine and cancers. These studies will provide more efficient therapeutic approaches to cope with racial and personal differences. Based on the resources in omics of our center, we will combine with expertise of informatics and structural biology to form a strong group to answer these questions. Owing to rapid interflow and climate change worldwide, we still face the challenge of threat of emerging and reemerging infectious diseases. We will develop new therapeutic methods to irradiate the reemerging and old infectious diseases. Moreover, not all infectious microbes are pathogenic. Human commensal microbes may participate in and alter development, immune maturation, disease formation and treatment outcome. Therefore, we will also study function of microbiota. Overloaded stress can be pathogenic in different diseases. Mitochondrion is a stress sensor in eukaryotes. We will establish new image systems coupled with omic approaches to integrate mitochondria responses to different stresses. The identified signal pathways can provide new biomarkers for prediction/prevention and targets for treatment. Furthermore, alterations in mitochondrial signals that affect the genome stability of cells and the interplay between microenvironment and immune system will be accessed for their contribution to cancer progression and therapeutic response. Hence, basic research in stress medicine will harness the exploration towards new markers and therapeutic design for diseases involving mitochondrial alterations. Microenvironment of cancers, especially the interplay with the immune system, plays the key role in cancer progression and drug resistance. Given that only a small fraction of patients display positive response to immunotherapy, using novel biomarker to select right patient for treatment is of vital importance. We will collect patients’ cancer tissues, nearby immunological tissues and bloods, characterize immune microenvironment including the subtypes and spacial distribution of T cells or other immune cells, and analyze mutation pattern of tumor cells and correlate to outcome of immunotherapy. Liver, head and neck and lung cancers will be focused. We will also use patients’ samples to examine their mutated genes and match T cell receptors isolated from single cell sorting. Cancer Hospital will link the whole NTU system to cultivate medical leaders and research elites to dissect the cause of diseases and solve the current difficulty in clinical therapy. We will take charge in genotyping, marker hunting, diagnosis advance, medical device and drug development. We will collaborate with related corporations and government organizations to train clinical experts, high level researchers and leaders. Our center currently executes SPARK program. We will train members in other universities or industrial companies. Our omic platform will connect not only the whole research systems in multi-disciplinal field of NTU, but also resources in corporations and government organizations in the Biotechnique Parks, to assist Taiwan to train talent elites.